Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

AIMS: Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and preserved ejection fraction. This study aims to evaluate if systolic blood pressure (SBP) moderates these effects. METHODS AND RESULTS: The association of SBP and the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Böhm, Michael, Anker, Stefan, Mahfoud, Felix, Lauder, Lucas, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J, Brueckmann, Martina, Saloustros, Ilias, Schüler, Elke, Wanner, Christoph, Zannad, Faiez, Packer, Milton, Butler, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890225/
https://www.ncbi.nlm.nih.gov/pubmed/36478225
http://dx.doi.org/10.1093/eurheartj/ehac693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890225/
https://www.ncbi.nlm.nih.gov/pubmed/36478225
http://dx.doi.org/10.1093/eurheartj/ehac693

Ejemplares similares